Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia.

Chan O, Talati C, Isenalumhe L, Shams S, Nodzon L, Fradley M, Sweet K, Pinilla-Ibarz J.

Blood Adv. 2020 Feb 11;4(3):530-538. doi: 10.1182/bloodadvances.2019000268.

PMID:
32045474
2.

How I treat newly diagnosed acute myeloid leukemia in an outpatient setting: a multidisciplinary team perspective.

Talati C, Frantz D, Lubas A, Salamanca C, Tobon K, Kubal T.

Future Oncol. 2020 Jan 27. doi: 10.2217/fon-2019-0781. [Epub ahead of print]

PMID:
31985277
3.

Tumor protein 53 mutations in acute myeloid leukemia: conventional induction chemotherapy or novel therapeutics.

Asghari H, Talati C.

Curr Opin Hematol. 2020 Mar;27(2):66-75. doi: 10.1097/MOH.0000000000000568.

PMID:
31922971
4.

Evidence-Based Guideline on Laparoscopy in Pregnancy: Commissioned by the British Society for Gynaecological Endoscopy (BSGE) Endorsed by the Royal College of Obstetricians & Gynaecologists (RCOG).

Ball E, Waters N, Cooper N, Talati C, Mallick R, Rabas S, Mukherjee A, Sri Ranjan Y, Thaha M, Doodia R, Keedwell R, Madhra M, Kuruba N, Malhas R, Gaughan E, Tompsett K, Gibson H, Wright H, Gnanachandran C, Hookaway T, Baker C, Murali K, Jurkovic D, Amso N, Clark J, Thangaratinam S, Chalhoub T, Kaloo P, Saridogan E.

Facts Views Vis Obgyn. 2019 Mar;11(1):5-25.

5.

Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients.

Mangaonkar AA, Swoboda DM, Coltro G, Lasho TL, Novotny PJ, Pophali P, Carr RM, Binder M, Finke CM, Gangat N, Al-Kali A, Begna KH, Reichard KK, Ketterling RP, Al Ali NH, Vafaii P, Zhang L, Padron E, Talati C, Patnaik MM.

Leukemia. 2020 Feb;34(2):656-661. doi: 10.1038/s41375-019-0574-x. Epub 2019 Sep 11. No abstract available.

PMID:
31511613
6.

Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis.

Kuykendall AT, Talati C, Padron E, Sweet K, Lancet JE, List AF, Sallman D, Komrokji RS.

Am J Hematol. 2019 Dec;94(12):E314-E317. doi: 10.1002/ajh.25625. Epub 2019 Sep 10. No abstract available.

PMID:
31444809
7.

Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia.

Talati C, Dhulipala VC, Extermann MT, Ali NA, Kim J, Komrokji R, Sweet K, Kuykendall A, Sehovic M, Reljic T, Djulbegovic B, Lancet JE.

Haematologica. 2020 Jan 31;105(2):398-406. doi: 10.3324/haematol.2018.208637. Print 2020.

8.

Can increased immunogenicity in chronic myeloid leukemia improve outcomes?

Chan O, Talati C, Sweet K, Pinilla-Ibarz J.

Expert Rev Hematol. 2019 Apr;12(4):225-233. doi: 10.1080/17474086.2019.1588105. Epub 2019 Mar 11.

PMID:
30855193
9.

Nuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectives.

Talati C, Sweet KL.

Int J Hematol Oncol. 2018 Sep 11;7(3):IJH04. doi: 10.2217/ijh-2018-0001. eCollection 2018 Oct. Review.

10.

Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients.

Kuykendall AT, Talati C, Padron E, Sweet K, Sallman D, List AF, Lancet JE, Komrokji RS.

Am J Hematol. 2019 Jan;94(1):87-92. doi: 10.1002/ajh.25335. Epub 2018 Nov 25.

11.

Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.

Pavlovsky C, Chan O, Talati C, Pinilla-Ibarz J.

Future Oncol. 2019 Jan;15(3):257-269. doi: 10.2217/fon-2018-0371. Epub 2018 Sep 25. Review.

PMID:
30251548
12.

Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.

Talati C, Sweet K.

Leuk Res. 2018 Oct;73:58-66. doi: 10.1016/j.leukres.2018.09.001. Epub 2018 Sep 8. Review.

13.

SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q.

Talati C, Sallman D, List AF.

Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):629-635. doi: 10.1016/j.clml.2018.07.293. Epub 2018 Jul 30. Review.

PMID:
30097406
14.

The Effect of Intermittent Oxytocin Pretreatment on Oxytocin-Induced Contractility of Human Myometrium In Vitro.

Talati C, Carvalho JCA, Luca A, Balki M.

Anesth Analg. 2019 Apr;128(4):671-678. doi: 10.1213/ANE.0000000000002834.

PMID:
29401080
15.

CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia.

Talati C, Lancet JE.

Future Oncol. 2018 May;14(12):1147-1154. doi: 10.2217/fon-2017-0603. Epub 2018 Jan 30. Review.

PMID:
29378418
16.

Resistance in chronic myeloid leukemia: definitions and novel therapeutic agents.

Talati C, Pinilla-Ibarz J.

Curr Opin Hematol. 2018 Mar;25(2):154-161. doi: 10.1097/MOH.0000000000000403. Review.

PMID:
29266016
17.

Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation.

Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS.

Ann Hematol. 2018 Mar;97(3):435-441. doi: 10.1007/s00277-017-3194-4. Epub 2017 Nov 30.

PMID:
29189896
18.

Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.

Talati C, Sallman D, List A.

Semin Hematol. 2017 Jul;54(3):159-166. doi: 10.1053/j.seminhematol.2017.06.003. Epub 2017 Jun 22. Review.

PMID:
28958290
19.

The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval.

Kuykendall AT, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e45-e53. doi: 10.1016/j.clml.2017.08.002. Epub 2017 Aug 5.

PMID:
28869184
20.

Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.

Sandoval-Sus JD, Chavez JC, Dalia S, Naqvi SMH, Talati C, Nodzon L, Kharfan-Dabaja MA, Pinilla-Ibarz J.

Leuk Lymphoma. 2018 Jan;59(1):59-68. doi: 10.1080/10428194.2017.1323271. Epub 2017 Jun 22.

PMID:
28641468
21.

Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy.

Kim DW, Talati C, Kim R.

J Gastrointest Oncol. 2017 Apr;8(2):256-265. doi: 10.21037/jgo.2016.09.07. Review.

22.

Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis.

Talati C, Zhang L, Shaheen G, Kuykendall A, Ball M, Zhang Q, Lancet JE, Zuckerman KS, List AF, Komrokji R, Moscinski L, Padron E.

Blood. 2017 Mar 30;129(13):1881-1883. doi: 10.1182/blood-2016-12-753210. Epub 2017 Feb 3. No abstract available.

PMID:
28159734
23.

The Use of Ultrasonography in Obstetric Anesthesia.

Talati C, Arzola C, Carvalho JC.

Anesthesiol Clin. 2017 Mar;35(1):35-58. doi: 10.1016/j.anclin.2016.09.005. Review.

PMID:
28131119
24.

Obstetric and Anaesthesia Checklists for the Management of Morbidly Adherent Placenta.

Walker MG, Pollard L, Talati C, Carvalho JC, Allen LM, Kachura J, Murji A, Kingdom JC, Windrim R.

J Obstet Gynaecol Can. 2016 Nov;38(11):1015-1023. doi: 10.1016/j.jogc.2016.08.015. Review.

PMID:
27969554
25.

An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T.

Talati C, Padron E.

Curr Hematol Malig Rep. 2016 Dec;11(6):425-433. doi: 10.1007/s11899-016-0350-1. Review.

PMID:
27664113
26.

Whole-genome sequencing of a malignant granular cell tumor with metabolic response to pazopanib.

Wei L, Liu S, Conroy J, Wang J, Papanicolau-Sengos A, Glenn ST, Murakami M, Liu L, Hu Q, Conroy J, Miles KM, Nowak DE, Liu B, Qin M, Bshara W, Omilian AR, Head K, Bianchi M, Burgher B, Darlak C, Kane J, Merzianu M, Cheney R, Fabiano A, Salerno K, Talati C, Khushalani NI, Trump DL, Johnson CS, Morrison CD.

Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000380. doi: 10.1101/mcs.a000380.

27.

The Effect of Extracellular Calcium on Oxytocin-Induced Contractility in Naive and Oxytocin-Pretreated Human Myometrium In Vitro.

Talati C, Ramachandran N, Carvalho JC, Kingdom J, Balki M.

Anesth Analg. 2016 May;122(5):1498-507. doi: 10.1213/ANE.0000000000001264.

PMID:
27023765
28.

The Recovery Time of Myometrial Responsiveness After Oxytocin-Induced Desensitization in Human Myometrium In Vitro.

Balki M, Ramachandran N, Lee S, Talati C.

Anesth Analg. 2016 May;122(5):1508-15. doi: 10.1213/ANE.0000000000001268.

PMID:
27007079
29.

Polo-like kinase inhibitors in hematologic malignancies.

Talati C, Griffiths EA, Wetzler M, Wang ES.

Crit Rev Oncol Hematol. 2016 Feb;98:200-10. doi: 10.1016/j.critrevonc.2015.10.013. Epub 2015 Nov 4. Review.

PMID:
26597019
30.

Effect of Incorporation of Pretreatment Serum Carcinoembryonic Antigen Levels Into AJCC Staging for Colon Cancer on 5-Year Survival.

Thirunavukarasu P, Talati C, Munjal S, Attwood K, Edge SB, Francescutti V.

JAMA Surg. 2015 Aug;150(8):747-755. doi: 10.1001/jamasurg.2015.0871. Erratum in: JAMA Surg. 2019 Apr 1;154(4):368.

PMID:
26083632
31.

How we will treat chronic myeloid leukemia in 2016.

Talati C, Ontiveros EP, Griffiths EA, Wang ES, Wetzler M.

Blood Rev. 2015 Mar;29(2):137-42. doi: 10.1016/j.blre.2014.12.003. Epub 2014 Dec 17. Review.

32.

The Monitoring and Management of Severe Traumatic Brain Injury in the United Kingdom: Is there a Consensus?: A National Survey.

Wijayatilake DS, Talati C, Panchatsharam S.

J Neurosurg Anesthesiol. 2015 Jul;27(3):241-5. doi: 10.1097/ANA.0000000000000143.

PMID:
25493928
33.

Should we be undertaking routine combined spinal epidural anaesthesia for elective caesarean sections?

Talati C, Doraiswami M.

Br J Hosp Med (Lond). 2014 Apr;75(4):238. No abstract available.

PMID:
24727970

Supplemental Content

Loading ...
Support Center